Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
3.185
+0.125 (4.08%)
Mar 9, 2026, 1:18 PM EDT - Market open
Aclaris Therapeutics Employees
As of December 31, 2025, Aclaris Therapeutics had 73 total employees, including 69 full-time and 4 part-time employees. The number of employees increased by 9 or 14.06% compared to the previous year.
Employees
73
Change (1Y)
9
Growth (1Y)
14.06%
Revenue / Employee
$107,205
Profits / Employee
-$889,356
Market Cap
384.10M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 834 |
| Bicycle Therapeutics | 305 |
| Absci | 157 |
| Aura Biosciences | 109 |
| Armata Pharmaceuticals | 60 |
| PepGen | 57 |
| Shattuck Labs | 44 |
| Candel Therapeutics | 38 |
ACRS News
- 11 days ago - Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 13 days ago - Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052 - GlobeNewsWire
- 5 weeks ago - Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA) - GlobeNewsWire
- 2 months ago - Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052 - GlobeNewsWire
- 2 months ago - Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages Transcript - Seeking Alpha
- 2 months ago - Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development - GlobeNewsWire
- 2 months ago - Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) - GlobeNewsWire
- 3 months ago - Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire